

澳大利亚生物技术协会 澳大利亚医疗技术公司名录



公司介绍

公司名称: OncoSil Medical

主要联系人姓名: Daniel Kenny

主要联系人职务: 首席执行官兼董事总经理

公司网址: www.oncosil.com.au

公司地址: Suite 897, 1 Alfred Street, Sydney, NSW 2000

公司已上市:

公司简介

OncoSil Medical 是澳大利亚一家处于临床阶段的生命科学公司。本公司致力于在其专利技术平台基础上, 研制新型医用放射技术, 为病患提供更安全的治疗。

OncoSil Medical 开发中的主打产品是 OncoSil™。该产品属于三类医疗器械, 它可以直接植入到肿瘤内部, 产生局部放射场从而使肿瘤最大限度暴露于放射源下。

本公司还处于临床开发阶段, 距今为止已经开展了四个临床试验。目前我们正准备在全球大约十所临床中心开展一个重要的注册性研究。

OncoSil Medical 在澳大利亚证券交易所上市, 公司代码为“OSL”。更多的信息请访问 www.asx.com.au

关键技术或领先技术

OncoSil Medical 的核心技术包括运用放射性磷(P32)来控制患者的肿瘤生长。本公司的主打产品 OncoSil™ 的首选目标是胰腺癌和肝癌。

OncoSil™ 将多孔硅质微球与磷混合, 经辐射产生的 P32 磷, 产生放射性微球。这些微球与专利的悬浮液混合后可直接注射到肿瘤内。P32 在几周内, 通过放射 β 粒子杀死分裂中的肿瘤细

胞。OncoSil™ 植入到肿瘤的内部，从内向外辐射肿瘤。与从外向内辐射肿瘤的外部 X 射线治疗相比，OncoSil™ 能提供更密集，更有针对性的 β 粒子辐射治疗。

类别

设备类：肿瘤学

关键或领先技术的发展阶段

临床试验阶段

合作机会

--

Directory of Australian medtech companies



COMPANY DETAILS

Company name: OncoSil Medical

Key contact name: Daniel Kenny

Job title of key contact: CEO/Managing Director

Company website address: www.oncosil.com.au

Company address: Suite 807, 1 Alfred Street, Sydney, NSW 2000

The company is Listed.

ABOUT THE COMPANY

OncoSil Medical is a clinical-stage Australian lifesciences company with the aim to provide new technologies for safer medical radiation treatments based on its proprietary technology platform.

OncoSil Medical's lead product in development is OncoSil™, a class III medical device which can be implanted directly into tumours to create a local radiation field that maximizes tumour exposure to radiation.

The company is in clinical stage development having conducted four clinical studies to date, and is in the process of commencing a pivotal registration study to be conducted in approximately ten clinical centers around the globe.

OncoSil Medical is listed on the Australian Stock Exchange (ASX) under the code "OSL" Further information is on www.asx.com.au

KEY OR LEAD TECHNOLOGY

OncoSil Medical's core technology includes the application of radioactive phosphorus (P32) to patients to control tumour growth. The Company's lead product is OncoSil™ with the first target indication being pancreatic and primary liver cancer.

OncoSil™, the product, contains porous silicon microspheres mixed with phosphorus and irradiated to create phosphorus 32 (P32) containing radioactive beads. These microparticles are mixed with a proprietary suspending fluid, and injected directly into the tumour. P32 emits beta particle radiation over a few weeks, killing dividing tumour cells. OncoSil™ is introduced into the middle of a tumour. External beam x-ray treatment irradiates the tumour from the "outside in". In contrast, OncoSil™ irradiates the tumour from the "inside out". The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation.

Category

Devices: Oncology

Point of development of key or lead technology

In clinical trials

OPPORTUNITIES SOUGHT

--